3rd EDITION - ICON plc

Jun 5, 2017 - Patient 1: Advanced NSCLC, no genomic markers, PD- .... economics are key to making that hap- pen.” retrieved using 1 mL, 2 mL or 4 mL of.
1MB Sizes 7 Downloads 248 Views
COD17.June5.Day3_Layout 1 5/17/17 2:47 PM Page 1

3rd EDITION

Monday June 5, 2017

Chicago • FREE

AboGen Announces Release of the GoPath Laboratories Positions S3® Saliva Collection System: The Itself as a Leader in NGS Holy Grail of Sample Collection Cancer Diagnostics

The Burden of Choice: ICON Oncology’s Opinion of How We Can Reach for the Stars With a Moonshot

AboGen developed and is now commercializing its disruptive S3® Saliva Collection System, which preserves all components of saliva including cells, white blood cells, serum proteins, extracellular material (cell free DNA and RNA, exosomes) and microbiota for several months at ambient shipping and storage

Contributing Authors: Dr. Martin Lachs — VP Project Management, Oncology & Haematology, ICON Dr. Reinhard Eisebitt — SVP, Innovation Centre, ICON Dr. Valerii Fedorov — VP, Innovation Centre, ICON

Article Courtesy of AboGen

continued on page 30

GPS Cancer™ Advanced Molecular Profiling: DNA + RNA + Protein — See it at NantWorks Booth #19135

Patient 1: Advanced NSCLC, no genomic markers, PDL1 negative — What do you do next? Patient 2: Metastatic breast cancer, HER2 positive, no response to anti-HER2 therapies — What do you do next?

GoPath Laboratories, a patient-centric molecular diagnostic and anatomic pathology laboratory, announces the development of two new NGS-based testing series designed to detect genetic changes in both solid tumors and hereditary cancers: OncoTargetTM and GeneticsNowTM. These comprehensive assays confirm GoPath as a leader in cutting-edge molecular cancer diagnostics and continues the company’s tradition of serving clients with a bet-

continued on page 30

Q&A with Dr. Maher Albitar, SVP, CMO and Director of R&D at NeoGenomics

Q: What have been the biggest advances in molecular diagnostics and medicine since ASCO 2016?

Know More Before — The Era of Complete Genomics and Proteomics is here When faced with a difficult treatment decision, GPS Can-

A: Some major advances are the fact that new biomarkers for predicting response to immunotherapy are evolving and more data is accumulating to support the value of these molecular biomarkers. Over the past year, tumor mutational burden has become a more promi-

Intermountain Precision Genomics Announces Translational Science Center

Rigel Announces Tavalisse™ as Proprietary Name for Fostamatinib in the United States

continued on page 43

SAINT GEORGE, Utah — Intermountain Precision Genomics announces the creation of a Translational Science Center (TSC) within the Intermountain Healthcare system. The center will house several of the latest highthroughput next-generation sequencing instruments for large-scale whole genome sequencing. This initiative comes as Intermountain’s next step to bring personalized medicine from the lab bench to clinical practice

continued on page 43

continued on page 43

SOUTH SAN FRANCISCO, Calif. — Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) announced that the U.S. Food and Drug Administration (FDA) has conditionally accepted the proprietary name Tavalisse™ for the company's investigational product candidate, fostamatinib disodium, an oral spleen tyrosine kinase (SYK) inhibitor. In addition, Rigel has applied to the U.S. Patent and Trademark Office to obtain federal registration of the Tavalisse mark. The name Tavalisse was developed based on the FDA’s Guidance for Industry, Contents of a Complete

continued on page 41

Making the right choice of clinical trial is becoming

continued on page 46

Exciting Times for Cancer Researchers in The US Oncology Network

By C. Lance Cowey, MD, oncologist and cancer researcher with Texas Oncology, an affiliate of The US Oncology Network

As a physician researcher affil